XNYSUSNA
Market cap639mUSD
Jan 14, Last price
33.55USD
1D
-1.35%
1Q
-8.56%
Jan 2017
-45.18%
Name
USANA Health Sciences Inc
Chart & Performance
Profile
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2022‑00 | 2021‑00 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2016‑00 | |
Income | |||||||||
Revenues | 921,010 -22.37% | 998,601 -11.99% | |||||||
Cost of revenue | 445,128 | 902,550 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 475,882 | 96,051 | |||||||
NOPBT Margin | 51.67% | 9.62% | |||||||
Operating Taxes | 38,665 | 39,271 | |||||||
Tax Rate | 8.12% | 40.89% | |||||||
NOPAT | 437,217 | 56,780 | |||||||
Net income | 63,788 -45.25% | 69,350 -44.37% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (11,599) | (25,382) | |||||||
BB yield | 1.12% | 2.47% | |||||||
Debt | |||||||||
Debt current | 8,064 | 6,892 | |||||||
Long-term debt | 7,278 | 14,572 | |||||||
Deferred revenue | (7,680) | ||||||||
Other long-term liabilities | 12,158 | 14,173 | |||||||
Net debt | (315,078) | (269,856) | |||||||
Cash flow | |||||||||
Cash from operating activities | 70,641 | 103,902 | |||||||
CAPEX | (14,494) | (10,400) | |||||||
Cash from investing activities | (11,975) | (12,370) | |||||||
Cash from financing activities | (14,237) | (30,088) | |||||||
FCF | 439,183 | 59,452 | |||||||
Balance | |||||||||
Cash | 330,420 | 288,420 | |||||||
Long term investments | 2,900 | ||||||||
Excess cash | 284,370 | 241,390 | |||||||
Stockholders' equity | 431,541 | 378,868 | |||||||
Invested Capital | 233,054 | 197,940 | |||||||
ROIC | 203.96% | 29.20% | |||||||
ROCE | 91.17% | 21.66% | |||||||
EV | |||||||||
Common stock shares outstanding | 19,345 | 19,310 | |||||||
Price | 53.60 -47.04% | 53.20 -31.00% | |||||||
Market cap | 1,036,892 -49.63% | 1,027,292 -37.32% | |||||||
EV | 721,814 | 757,436 | |||||||
EBITDA | 496,277 | 117,461 | |||||||
EV/EBITDA | 1.45 | 6.45 | |||||||
Interest | 262 | 192 | |||||||
Interest/NOPBT | 0.06% | 0.20% |